Centogene Extends Genetic Testing Partnership With Takeda
April 11 2023 - 7:20AM
Dow Jones News
By Chris Wack
Centogene N.V. said Tuesday that it has extended its partnership
with Takeda Pharmaceutical Co. to diagnose patients with Lysosomal
Storage Disorders.
Under the renewed one-year partnership agreement, Centogene will
continue to provide Takeda with access to diagnostic testing for
patients around the world.
The aim of the commercial fee-for-service agreement is to
enhance patient access to rapid and reliable diagnostics for LSDs,
including Fabry disease, Gaucher disease and Hunter syndrome.
In January 2015, Centogene originally entered into an agreement
with Shire Pharmaceuticals, which was bought in 2019 by Takeda, to
provide diagnostic testing capability to enhance early diagnosis of
patients suffering from rare genetic diseases. Last year, the
contract was extended until March 2023.
Centogene shares were up 15% at 75 cents in premarket
trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 11, 2023 07:05 ET (11:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jul 2023 to Jul 2024